Natalia Pereira de Oliveira, Luciano de Melo Pompei
{"title":"更年期激素治疗和血清素再摄取抑制剂的效果。","authors":"Natalia Pereira de Oliveira, Luciano de Melo Pompei","doi":"10.1080/13697137.2025.2486051","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Postmenopausal hypoestrogenism may cause significant changes in the oral cavity, interfering with inflammatory mechanisms such as salivary secretion. This study aimed to compare the salivary flow, pH levels and prevalence of dry mouth in postmenopausal women treated with hormone replacement therapy (HRT), those treated with selective serotonin reuptake inhibitors (SSRIs) and those without treatment.</p><p><strong>Methods: </strong>Ninety postmenopausal women participated in the study. Of these, 30 used HRT, 30 used SSRIs and 30 did not receive any treatment (control). Salivary flow was measured using stimulated sialometry, while the pH level was measured using pH strips. Meanwhile, a questionnaire was used to assess for xerostomia.</p><p><strong>Results: </strong>The salivary flow measurements were 1.66 ± 0.49 ml/min for the HRT group, 1.23 ± 0.50 ml/min for the SSRI group and 1.68 ± 0.65 ml/min for the control group (<i>p</i> = 0.005 for comparison). The pH values were 7.13 ± 0.43, 7.0 ± 0.26 and 6.97 ± 0.41 for the HRT, SSRI and control groups, respectively. Xerostomia was reported in 60% of women receiving HRT, 46.7% receiving SSRIs and 26.7% of the controls (<i>p</i> = 0.033).</p><p><strong>Conclusion: </strong>Women using SSRIs had lower salivary flow than the HRT or control group. However, xerostomia was more prevalent in women receiving HRT.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"1-5"},"PeriodicalIF":2.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of menopause hormone therapy and serotonin reuptake inhibitors.\",\"authors\":\"Natalia Pereira de Oliveira, Luciano de Melo Pompei\",\"doi\":\"10.1080/13697137.2025.2486051\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Postmenopausal hypoestrogenism may cause significant changes in the oral cavity, interfering with inflammatory mechanisms such as salivary secretion. This study aimed to compare the salivary flow, pH levels and prevalence of dry mouth in postmenopausal women treated with hormone replacement therapy (HRT), those treated with selective serotonin reuptake inhibitors (SSRIs) and those without treatment.</p><p><strong>Methods: </strong>Ninety postmenopausal women participated in the study. Of these, 30 used HRT, 30 used SSRIs and 30 did not receive any treatment (control). Salivary flow was measured using stimulated sialometry, while the pH level was measured using pH strips. Meanwhile, a questionnaire was used to assess for xerostomia.</p><p><strong>Results: </strong>The salivary flow measurements were 1.66 ± 0.49 ml/min for the HRT group, 1.23 ± 0.50 ml/min for the SSRI group and 1.68 ± 0.65 ml/min for the control group (<i>p</i> = 0.005 for comparison). The pH values were 7.13 ± 0.43, 7.0 ± 0.26 and 6.97 ± 0.41 for the HRT, SSRI and control groups, respectively. Xerostomia was reported in 60% of women receiving HRT, 46.7% receiving SSRIs and 26.7% of the controls (<i>p</i> = 0.033).</p><p><strong>Conclusion: </strong>Women using SSRIs had lower salivary flow than the HRT or control group. However, xerostomia was more prevalent in women receiving HRT.</p>\",\"PeriodicalId\":10213,\"journal\":{\"name\":\"Climacteric\",\"volume\":\" \",\"pages\":\"1-5\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Climacteric\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/13697137.2025.2486051\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Climacteric","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13697137.2025.2486051","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
Effect of menopause hormone therapy and serotonin reuptake inhibitors.
Objective: Postmenopausal hypoestrogenism may cause significant changes in the oral cavity, interfering with inflammatory mechanisms such as salivary secretion. This study aimed to compare the salivary flow, pH levels and prevalence of dry mouth in postmenopausal women treated with hormone replacement therapy (HRT), those treated with selective serotonin reuptake inhibitors (SSRIs) and those without treatment.
Methods: Ninety postmenopausal women participated in the study. Of these, 30 used HRT, 30 used SSRIs and 30 did not receive any treatment (control). Salivary flow was measured using stimulated sialometry, while the pH level was measured using pH strips. Meanwhile, a questionnaire was used to assess for xerostomia.
Results: The salivary flow measurements were 1.66 ± 0.49 ml/min for the HRT group, 1.23 ± 0.50 ml/min for the SSRI group and 1.68 ± 0.65 ml/min for the control group (p = 0.005 for comparison). The pH values were 7.13 ± 0.43, 7.0 ± 0.26 and 6.97 ± 0.41 for the HRT, SSRI and control groups, respectively. Xerostomia was reported in 60% of women receiving HRT, 46.7% receiving SSRIs and 26.7% of the controls (p = 0.033).
Conclusion: Women using SSRIs had lower salivary flow than the HRT or control group. However, xerostomia was more prevalent in women receiving HRT.
期刊介绍：
Climacteric is the official journal of the International Menopause Society (IMS). As an international peer-reviewed journal it publishes original research and reviews of all aspects of aging in women.
Climacteric was founded by the IMS in 1998 and today has become a leading journal in the publication of peer-reviewed papers on the menopause, climacteric and mid-life health. Topics covered include endocrine changes, symptoms attributed to the menopause and their treatment, hormone replacement and alternative therapies, lifestyles, and the counselling and education of peri- and postmenopausal women. Climacteric, published bimonthly, also features regular invited reviews, editorials and commentaries on recent developments.
The editorial review board of Climacteric includes leading scientific and clinical experts in the field of midlife medicine and research and is headed by its Editor-in-Chief, Professor Rod Baber of Australia. He and his team of Associate Editors act independently to set a clear editorial policy, co-ordinate peer review, and ensure a rapid response to submitted papers.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
